Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: Effect on myocardial angiogenesis

Cardiovascular Research

Volumn 44, Issue 2, 1999, Pages 294-302

  Lazarous, Daisy F ^a,b   Shou, Matie ^a   Stiber, Jonathan A ^a   Hodge, Everett ^a   Thirumurti, Venugopal ^a   Gonçalves, Lino ^a   Unger, Ellis F ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Collateral circulation; Coronary circulation; Gene therapy; Growth factors; Ischemia

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOG; FEMALE; GENE TRANSFER; HISTOLOGY; MALE; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TECHNIQUE;

EID: 0033231797     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00203-5     Document Type: Article

References (37)

1. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
2. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
3. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
4. Plate K., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
5. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 92:1995;10457-10461.
6. Stone J., Itin A., Alon T., et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 15:1995;4738-4747.
7. Pe'er J., Shweiki D., Itin A., et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 72:1995;638-645.
8. Bauters C., Asahara T., Zheng L.P., et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol. 267:1994;H1263-1271.
9. Takeshita S., Zheng L.P., Brogi E., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 93:1994;662-670.
10. Takeshita S., Pu L.Q., Stein L.A., et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 90:1994;II228-II234.
11. Asahara T., Bauters C., Zheng L.P., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 92:1995;II365-II371.
12. Bauters C., Asahara T., Zheng L.P., et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 21:1995;314-324.
13. Banai S., Jaklitsch M.T., Shou M., et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 89:1994;2183-2189.
14. Harada K., Friedman M., Lopez J.J., et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 270:1996;H1791-H1802.
15. Hariawala M.D., Horowitz J.J., Esakof D., et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 63:1996;77-82.
16. Lazarous D.F., Shou M., Scheinowitz M., et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
17. Woody M., Mehdi K., Zipes D.P., et al. High efficiency adenovirus-mediated pericardial gene transfer in vivo [abstract]. J Am Coll Cardiol. 27:(Suppl A):1996;31A.
18. National Research Council . Guide for the care and use of laboratory animals. 1996;National Academy Press, Washington, DC.
19. Dulbecco E., Ginsberg A., Virology. 1980;881 Harper and Row, New York.
20. Guzman R.J., Lemarchand P., Crystal R.G., Epstein S.E., Finkel T. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res. 73:1993;1202-1207.
21. Heymann M.A., Payne B.D., Hoffman J.I.E., Rudolph A.M. Blood flow measurements with radionuclide-labelled particles. Prog Cardiovasc Dis. 20:1977;55-79.
22. Austin G.E., Tuvlin M.B., Martino-Salzman D., Hunter R., Justicz A.G. Determination of regional myocardial blood flow using fluorescent microspheres. Am J Cardiovasc Pathol. 4:1993;352-357.
23. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 265:1993;H586-H592.
24. Isner J.M., Walsh K., Symes J., et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease [news]. Circulation. 91:1995;2687-2692.
25. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
26. 165 [abstract]. J Am Coll Cardiol. 27:(Suppl A):1996;1A.
27. Rade J.J., Schulick A.H., Virmani R., Dichek D.A. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 2:1996;293-298.
28. Muhlhauser J., Merrill M.J., Pili R., et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 77:1995;1077-1086.
29. French B.A., Mazur W., Geske R.S., Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 90:1994;2414-2424.
30. Giordano F.J., Ping P., McKirnan M.D., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 2:1996;534-539.
31. Gilgenkrantz H., Duboc D., Juillard V., et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther. 6:1995;1265-1274.
32. Landau C., Jacobs A.K., Haudenschild C.C. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am Heart J. 129:1995;924-931.
33. Uchida Y., Yanagisawa-Miwa A., Nakamura F., et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study. Am Heart J. 130:1995;1182-1188.
34. Cohen T., Gitay-Goren H., Sharon R. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem. 270:1995;11322-11326.
35. Terman B., Khandke L., Dougher-Vermazan M., et al. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. Growth Factors. 11:1994;187-195.
36. Schwarz E.R., Spealman M.T., Patterson M., et al. Effect of intra myocardial injection of DNA expressing vascular endothelial growth factor in myocardial infarct tissue in the rat heart: angiogenesis and angioma formation. Circulation. 456:(Suppl 1):1998;2397.
37. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., Blau H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. 2:1998;549-558.